Benjamin M. Ellingson1, Timothy F. Cloughesy2, Albert Lai2, Phioanh L. Nghiemphu2, Whitney B. Pope1
There remains a significant need for sensitive biomarkers that predict response to anti-angiogenic treatment for malignant gliomas. We hypothesize that graded functional diffusion maps (fDMs) are a sensitive biomarker for early prediction of bevacizumab failure in recurrent glioblastoma (GBM). Eighty-five patients with recurrent GBMs were retrospectively examined. The volume of fDM-classified hypo- and hypercellular tissue in various categories were tested to determine if they were predictive of survival. Using graded fDMs, patients having a large volume of voxels exhibiting a subtle decrease in ADC had a significantly shorter progression-free and overall survival compared to those having a lower volume.